Intraoperative Cardiac Events During Pediatric Cardiac Magnetic Resonance Imaging Under Anesthesia: A Retrospective Cohort Study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Intraoperative Cardiac Complications in Pediatric Patients Undergoing Magnetic Resonance Imaging with Anesthesia: A Retrospective Analysis

  • By

  • Theodora Wingert

  • Justine Liang

  • Kelly Feldman

  • Amelie Delaporte

  • Christine Nguyen-Buckley

  • Tristan Grogan

  • Alexandre Joosten

  • John Paul Finn

  • Ihab Ayad

  • June 19, 2026

Share

  • 1

    Congenital heart disease (CHD) affects approximately 1% of live births, making it a common congenital condition requiring careful perioperative management.

  • 2

    Cardiac MRI in young children typically necessitates general anesthesia, presenting unique challenges that may increase the risk of intraoperative complications.

  • 3

    Children with CHD undergoing noncardiac surgery experience higher perioperative complication rates compared to those without CHD.

  • 4

    The study aims to determine the incidence of intraoperative cardiac events during cardiac MRI with anesthesia in pediatric patients.

  • 5

    Intraoperative cardiac events are defined as hemodynamic instability or severe adverse cardiac events, assessed using a composite framework.

Original Source(s)

Intraoperative Cardiac Events During Pediatric Cardiac Magnetic Resonance Imaging Under Anesthesia: A Retrospective Cohort Study

  • by Theodora Wingert, Justine Liang, Kelly Feldman, Amelie Delaporte, Christine Nguyen-Buckley, Tristan Grogan, Alexandre Joosten, John Paul Finn, Ihab Ayad

  • June 19, 2026

Related Content

Caffeine and the Young Heart A Systematic Review of Arrhythmogenic Risks in Children and Adolescents

Quality improvement: prevention of cardiac arrest in children with heart disease on the paediatric intensive care unit

10 CMS and FDA Actions Affecting Care in 2026

From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.